drugset / Trial / NCT00560378

Long-term Safety of Protopic in Atopic Eczema

NCT00560378

Phase 3 Completed 789 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients who have participated in previous studies with Tacrolimus ointment for atopic eczema are entitled to enter this four-year follow study to investigate the safety of treatment with Tacrolimus ointment 0.1%

Timeline

Start
1998-06
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.1 % Topical

Indications